新型碳青霉烯类药物比阿培南（L-627）对厌氧菌的体外活性
In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.
作者信息
Aldridge K E, Morice N, Schiro D D
机构信息
Department of Medicine, Louisiana State University Medical Center, New Orleans 70112.
出版信息
Antimicrob Agents Chemother. 1994 Apr;38(4):889-93. doi: 10.1128/AAC.38.4.889.
Abstract
We tested 441 clinical strains of anaerobes by using a broth microdilution method to determine the in vitro activity of biapenem for comparison with those of other agents. Biapenem had activity comparable to those of imipenem and meropenem against all groups of anaerobes with MICs for 90% of the strains tested of 0.06 to 2 micrograms/ml. Against the Bacteroides fragilis group, biapenem was more active than ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin, cefoxitin, cefotaxime, and ceftriaxone. Biapenem was also active against all of the B. capillosus, Prevotella, Clostridium, and Eubacterium strains and anaerobic cocci tested. Against all of the anaerobes tested, biapenem was 32- and 4-fold more active than clindamycin and metronidazole, respectively. These data indicate broad-spectrum activity by biapenem against anaerobes.
摘要
我们采用肉汤微量稀释法检测了441株厌氧菌临床菌株，以确定比阿培南的体外活性，并与其他药物进行比较。比阿培南对所有厌氧菌的活性与亚胺培南和美罗培南相当，90%受试菌株的MIC为0.06至2微克/毫升。在脆弱拟杆菌组中，比阿培南比氨苄西林-舒巴坦、替卡西林-克拉维酸、哌拉西林、头孢西丁、头孢噻肟和头孢曲松更具活性。比阿培南对所有检测的毛细拟杆菌、普雷沃菌属、梭菌属、真杆菌属菌株及厌氧球菌也有活性。在所有受试厌氧菌中，比阿培南的活性分别比克林霉素和甲硝唑高32倍和4倍。这些数据表明比阿培南对厌氧菌具有广谱活性。
相似文献
1
In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.新型碳青霉烯类药物比阿培南（L-627）对厌氧菌的体外活性
Antimicrob Agents Chemother. 1994 Apr;38(4):889-93. doi: 10.1128/AAC.38.4.889.
2
In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.比阿培南联合丝氨酸β-内酰胺酶抑制剂 RPX7009 对厌氧菌的体外活性。
Antimicrob Agents Chemother. 2013 Jun;57(6):2620-30. doi: 10.1128/AAC.02418-12. Epub 2013 Mar 25.
3
Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.脆弱拟杆菌群物种及其他厌氧菌对美罗培南、亚胺培南、哌拉西林、头孢西丁、氨苄西林/舒巴坦、克林霉素和甲硝唑的敏感性比较。
J Antimicrob Chemother. 1993 Mar;31(3):363-72. doi: 10.1093/jac/31.3.363.
4
In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.美罗培南与亚胺培南、甲硝唑、氨苄西林及氨苄西林/舒巴坦相比对厌氧菌的体外活性
Arzneimittelforschung. 1994 Jul;44(7):859-62.
5
The growth-inhibitory properties of meropenem against anaerobes of clinical importance.美罗培南对具有临床重要性厌氧菌的生长抑制特性。
J Antimicrob Chemother. 1989 Sep;24 Suppl A:119-24. doi: 10.1093/jac/24.suppl_a.119.
6
Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.新型碳青霉烯类药物比阿培南与亚胺培南、美罗培南及其他广谱β-内酰胺类药物的抗菌活性比较。
Eur J Clin Microbiol Infect Dis. 1993 May;12(5):384-91. doi: 10.1007/BF01964439.
7
Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers.美罗培南及部分对照药物在北美七个中心针对厌氧菌的抗菌活性
Clin Infect Dis. 1993 Jun;16 Suppl 4:S361-6. doi: 10.1093/clinids/16.supplement_4.s361.
8
In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates.美罗培南（SM-7338）、亚胺培南及其他五种抗生素对临床厌氧菌分离株的体外活性
Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):57-61. doi: 10.1016/0732-8893(90)90055-z.
9
10
Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.539株革兰氏阳性和革兰氏阴性厌氧菌对新型药物的敏感性，包括RP59500、比阿培南、曲伐沙星和哌拉西林/他唑巴坦。
J Antimicrob Chemother. 1993 Aug;32(2):223-31. doi: 10.1093/jac/32.2.223.
引用本文的文献
1
Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.印度南部阿贝卡星、头孢米诺、磷霉素、比阿培南及其他抗生素对革兰氏阴性临床分离株的最低抑菌浓度分布测定：一项前瞻性研究。
PLoS One. 2014 Jul 28;9(7):e103253. doi: 10.1371/journal.pone.0103253. eCollection 2014.
2
Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial.比阿培南与美罗培南治疗细菌感染的多中心、随机、对照临床试验
Indian J Med Res. 2013 Dec;138(6):995-1002.
3
Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa.铜绿假单胞菌中碳青霉烯耐药性产生的相关机制。
Hippokratia. 2012 Oct;16(4):303-7.
4
In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.比阿培南联合丝氨酸β-内酰胺酶抑制剂 RPX7009 对厌氧菌的体外活性。
Antimicrob Agents Chemother. 2013 Jun;57(6):2620-30. doi: 10.1128/AAC.02418-12. Epub 2013 Mar 25.
5
Biapenem.比阿培南
Drugs. 2002;62(15):2221-34; discussion 2235. doi: 10.2165/00003495-200262150-00005.
6
Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.亚胺培南/西司他丁：其抗菌活性、药代动力学及治疗严重感染疗效的最新进展
Drugs. 1996 Jan;51(1):99-136. doi: 10.2165/00003495-199651010-00008.
7
Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.美罗培南：抗菌活性、药代动力学特性及临床疗效综述
Drugs. 1995 Jul;50(1):73-101. doi: 10.2165/00003495-199550010-00007.
本文引用的文献
1
Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.新型碳青霉烯类药物比阿培南与亚胺培南、美罗培南及其他广谱β-内酰胺类药物的抗菌活性比较。
Eur J Clin Microbiol Infect Dis. 1993 May;12(5):384-91. doi: 10.1007/BF01964439.
2
In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.比阿培南对革兰氏阳性和革兰氏阴性菌临床分离株的体外活性。
Antimicrob Agents Chemother. 1993 Sep;37(9):2009-16. doi: 10.1128/AAC.37.9.2009.
3
Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.539株革兰氏阳性和革兰氏阴性厌氧菌对新型药物的敏感性，包括RP59500、比阿培南、曲伐沙星和哌拉西林/他唑巴坦。
J Antimicrob Chemother. 1993 Aug;32(2):223-31. doi: 10.1093/jac/32.2.223.
4
Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.硫霉素及相关碳青霉烯类抗生素在肾脏二肽酶即脱氢肽酶作用下的代谢
Antimicrob Agents Chemother. 1982 Jul;22(1):62-70. doi: 10.1128/AAC.22.1.62.
5
Properties of a new penicillinase type produced by Bacteroides fragilis.脆弱拟杆菌产生的一种新型青霉素酶的特性
Antimicrob Agents Chemother. 1982 Oct;22(4):579-84. doi: 10.1128/AAC.22.4.579.
6
Characterization of three different beta-lactamases from the Bacteroides fragilis group.脆弱拟杆菌群中三种不同β-内酰胺酶的特性分析。
Antimicrob Agents Chemother. 1980 Aug;18(2):220-5. doi: 10.1128/AAC.18.2.220.
7
Thienamycin: development of imipenen-cilastatin.硫霉素：亚胺培南-西司他丁的研发
J Antimicrob Chemother. 1983 Dec;12 Suppl D:1-35. doi: 10.1093/jac/12.suppl_d.1.
8
Beta-lactamase-mediated imipenem resistance in Bacteroides fragilis.脆弱拟杆菌中β-内酰胺酶介导的亚胺培南耐药性
Antimicrob Agents Chemother. 1986 Nov;30(5):645-8. doi: 10.1128/AAC.30.5.645.
9
Transfer of beta-lactamase-associated cefoxitin resistance in Bacteroides fragilis.脆弱拟杆菌中β-内酰胺酶相关的头孢西丁耐药性转移
Antimicrob Agents Chemother. 1986 May;29(5):918-20. doi: 10.1128/AAC.29.5.918.
10
In vitro activity of L-627 against anaerobic bacteria.L-627对厌氧菌的体外活性。
Eur J Clin Microbiol Infect Dis. 1992 Aug;11(8):757-60. doi: 10.1007/BF01989987.
Zotero 插件